Insmed (INSM) Other Non-Current Assets (2011 - 2026)
Insmed's (INSM) quarterly Other Non-Current Assets came in at $99.3 million in Q1 2026, up 10.6% year-on-year from $89.8 million in Q1 2025, and up 1.95% quarter-over-quarter from $97.4 million in Q4 2025.
Insmed (INSM) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Insmed's Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $99.3 million for Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 10.6% year-over-year to $99.3 million in Q1 2026; TTM through Mar 2026 was $99.3 million, a 10.6% increase from a year earlier, with the FY2025 full-year figure at $97.4 million, up 4.45% from the prior year.
- Other Non-Current Assets advanced to $99.3 million in Q1 2026 per INSM's latest filing, from $97.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $99.3 million in Q1 2026 and bottomed at $57.2 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $89.8 million (2025), against an average of $85.6 million.
- Across the five-year window, Other Non-Current Assets jumped 49.25% in 2022 and slipped 6.21% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $76.1 million in 2022, then gained by 26.9% to $96.6 million in 2023, then slipped by 3.47% to $93.2 million in 2024, then gained by 4.45% to $97.4 million in 2025, then increased by 1.95% to $99.3 million in 2026.
- Per Business Quant, the three latest INSM Other Non-Current Assets figures stand at $99.3 million (Q1 2026), $97.4 million (Q4 2025), and $91.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | 99.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.28 Mn |
| Dec 31, 2025 | 97.38 Mn |
| Sep 30, 2025 | 91.61 Mn |
| Jun 30, 2025 | 88.81 Mn |
| Mar 31, 2025 | 89.76 Mn |
| Dec 31, 2024 | 93.23 Mn |
| Sep 30, 2024 | 96.86 Mn |
| Jun 30, 2024 | 85.83 Mn |
| Mar 31, 2024 | 95.70 Mn |
| Dec 31, 2023 | 96.57 Mn |
| Sep 30, 2023 | 92.49 Mn |
| Jun 30, 2023 | 83.45 Mn |
| Mar 31, 2023 | 81.32 Mn |
| Dec 31, 2022 | 76.10 Mn |
| Sep 30, 2022 | 63.71 Mn |
| Jun 30, 2022 | 66.30 Mn |
| Mar 31, 2022 | 57.20 Mn |
| Dec 31, 2021 | 50.99 Mn |
| Sep 30, 2021 | 47.60 Mn |
| Jun 30, 2021 | 49.24 Mn |